High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab
2024Ophthalmology and TherapyJournalOpen access
10.1007/s40123-024-01022-wFull text1 citations
2024Ophthalmology and TherapyJournalOpen access
10.1007/s40123-024-01022-wFull text1 citations
4 authors across 3 institutions in 2 countries.
Assignment is probabilistic — a work belongs to several fields in proportions.
Several sources describing one work is the point — it means the record rests on more than one authority.
2024 · Ophthalmology and Therapy · 1 citations
https://openalex.org/W4402041302